Table 2.
Comparison of subjects with and without elevated response
| Elevated response for at least one IFN (>1500 AUs) | |||
|---|---|---|---|
| No | Yes | p value | |
| Group, n (row %) | |||
| APS1 | 0 (0%) | 19 (100%) | BD vs. AEFI: 0.734a |
| BD | 104 (98.1%) | 2 (1.9%) | |
| AEFI | 281 (96.9%) | 9 (3.1%) | |
| Age, mean ± SD | 55.4 ± 16.6 | 56 ± 14.8 | 0.970b |
| Sex, n (row %) | |||
| Female | 210 (96.3%) | 8 (3.7%) | 0.358a |
| Male | 175 (98.3%) | 3 (1.7%) | |
| Vaccine, n (row %) | |||
| None (BDs) | 104 (98.1%) | 2 (1.9%) | 0.057a |
| Comirnaty | 170 (98.3%) | 3 (1.7%) | |
| Spikevax | 33 (100%) | 0 (0%) | |
| Vaxzevria | 78 (92.9%) | 6 (7.1%) | |
| Vaccine dose, n (row %) | |||
| None (BDs) | 104 (98.1%) | 2 (1.9%) | 0.453a |
| Single dose | 200 (96.2%) | 8 (3.8%) | |
| Two doses | 81 (98.8%) | 1 (1.2%) | |
| Time from vaccination to AEFI (days), mean ± SD | 10.9 ± 11.6 | 5.3 ± 9 | 0.051b |
| Diagnosis category in the AEFI group, n (row %) | |||
| Coagulation | 96 (96%) | 4 (4%) | 0.072c |
| Neurologic | 52 (100%) | 0 (0%) | |
| Allergic | 25 (86.2%) | 4 (13.8%) | |
| Cardiac | 33 (100%) | 0 (0%) | |
| Other | 20 (100%) | 0 (0%) | |
| MACE | 16 (94.1%) | 1 (5.9%) | |
| Cytopenia | 17 (100%) | 0 (0%) | |
| Systemic disease | 10 (100%) | 0 (0%) | |
| Infection | 9 (100%) | 0 (0%) | |
| Vascular | 3 (100%) | 0 (0%) | |
P values have been calculated within the AEFI group (except for those concerning group, age, and sex).
IFN interferon, AU arbitrary unit, APS1 autoimmune polyendocrine syndrome type 1, BD blood donor, AEFI adverse event following immunization, MACE major adverse cardiac event.
aFisher’s exact test (2 × 2) or Freeman-Halton extension (2 × 3).
bMann–Whitney U test.
cLikelihood-ratio test.